Nevro Corp (NVRO) VP Sells $148,965.00 in Stock
Nevro Corp (NASDAQ:NVRO) VP Michael Enxing sold 1,500 shares of Nevro Corp stock in a transaction that occurred on Tuesday, October 4th. The stock was sold at an average price of $99.31, for a total value of $148,965.00. Following the completion of the sale, the vice president now directly owns 39,463 shares in the company, valued at approximately $3,919,070.53. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Michael Enxing also recently made the following trade(s):
- On Thursday, August 4th, Michael Enxing sold 1,500 shares of Nevro Corp stock. The stock was sold at an average price of $82.06, for a total value of $123,090.00.
Nevro Corp (NASDAQ:NVRO) opened at 96.42 on Wednesday. The company’s 50-day moving average price is $97.62 and its 200-day moving average price is $79.36. The stock’s market cap is $2.75 billion. Nevro Corp has a 12-month low of $36.51 and a 12-month high of $106.93.
Nevro Corp (NASDAQ:NVRO) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.31) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.16. The firm earned $55.40 million during the quarter, compared to analyst estimates of $45.11 million. The firm’s revenue was up 385.5% compared to the same quarter last year. On average, equities analysts expect that Nevro Corp will post ($1.42) EPS for the current fiscal year.
Large investors have recently modified their holdings of the stock. Sei Investments Co. boosted its stake in shares of Nevro Corp by 40.0% in the second quarter. Sei Investments Co. now owns 1,620 shares of the company’s stock worth $119,000 after buying an additional 463 shares during the last quarter. Fortaleza Asset Management Inc. purchased a new stake in shares of Nevro Corp during the second quarter worth $125,000. BNP Paribas Arbitrage SA boosted its stake in shares of Nevro Corp by 110.8% in the third quarter. BNP Paribas Arbitrage SA now owns 1,977 shares of the company’s stock worth $206,000 after buying an additional 1,039 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Nevro Corp by 130.1% in the second quarter. BlackRock Inc. now owns 2,487 shares of the company’s stock worth $183,000 after buying an additional 1,406 shares during the last quarter. Finally, Amalgamated Bank purchased a new stake in shares of Nevro Corp during the second quarter worth $247,000.
Several equities analysts have recently weighed in on the company. Zacks Investment Research raised Nevro Corp from a “hold” rating to a “buy” rating and set a $110.00 target price on the stock in a research report on Wednesday, October 5th. B. Riley assumed coverage on Nevro Corp in a research report on Wednesday, September 21st. They set a “buy” rating and a $114.00 target price on the stock. Piper Jaffray Cos. reissued an “overweight” rating and set a $112.00 target price (up previously from $98.00) on shares of Nevro Corp in a research report on Thursday, August 11th. JMP Securities boosted their target price on Nevro Corp from $90.00 to $110.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 9th. Finally, JPMorgan Chase & Co. boosted their target price on Nevro Corp from $84.00 to $100.00 and gave the company an “overweight” rating in a research report on Tuesday, August 9th. Eleven equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $104.00.
Nevro Corp Company Profile
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.
Receive News & Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related companies with MarketBeat.com's FREE daily email newsletter.